New York Life Investment Management’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

New York Life Investment Management’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-243,451	Closed	-$216K	–	1451
2022 Q4	$216K	Buy	243,451 +27,438	+13%	+$36.4K	﹤0.01%	1171
2022 Q3	$339K	Buy	216,013 +15,867	+8%	+$36K	﹤0.01%	1052
2022 Q2	$402K	Buy	+200,146	New	+$346K	﹤0.01%	958

Other funds holding SRNE

Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return

OCM

Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return

OFA

Oaktree Fund Advisors Los Angles, California $56.9M AUM 80.32% 1-Year Est. Return

CGA

Crescent Grove Advisors Lake Forest, Illinois $1.2B AUM 23.08% 1-Year Est. Return

LCM

Lattice Capital Management Kirkland, Washington $56.9M AUM 49.15% 1-Year Est. Return

STB

S&T Bank Indiana, Pennsylvania $333M AUM 106.39% 1-Year Est. Return

GoalVest Advisory New York $539M AUM 27.49% 1-Year Est. Return

HFRG

Houlihan Financial Resource Group Ashburn, Virginia $281M AUM 17.68% 1-Year Est. Return

VFA

Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return

GBWM

Granite Bay Wealth Management Portsmouth, New Hampshire $470M AUM 15.4% 1-Year Est. Return

New York Life Investment Management's SRNE Position: Q1 2023 in Review

New York Life Investment Management sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2023, closing a stake of 243,451 shares — an estimated $216K sold.

New York Life Investment Management first reported a position in SRNE in Q2 2022 and held it in 3 quarters. The position peaked at $402K in Q2 2022. 34 funds tracked by Wall St. Rank hold SRNE as of Q1 2023.

New York Life Investment Management reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
New York Life Investment Management sold 243,451 Sorrento Therapeutics, Inc. shares in Q1 2023, an estimated $216K.
New York Life Investment Management first reported a position in Sorrento Therapeutics, Inc. in Q2 2022 and held it in 3 quarters.
New York Life Investment Management's Sorrento Therapeutics, Inc. position peaked at $402K in Q2 2022.
34 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2023.

Based on New York Life Investment Management's 13F filing for Q1 2023, filed 8 May 2023.